Automated System Identification for Satellite Attitude Control

A novel approach to on-obit system identification of satellite attitude control dynamics is presented. The approach is fully automated and will thus enable a variety of satellite applications, including high-performance proliferated constellations and modular payloads. The key enabling feature of the approach is the ability to estimate the uncertainty in the model and then perform additional data collections specifically to reduce the uncertainty. A prototype software implementation of the algorithm accurately estimated multiple structural modes in a CubeSat simulation and a CubeSat reaction wheel testbed in preparation for an on-orbit demonstration as part of the The Aerospace Corporation’s Slingshot 1 mission

Fisheries Typical Production Units At Northwestern Mexico

To analyse and project the impact of structural, technological and political changes on food production, the Mexican Government, through the Secretary of Agriculture, Livestock, Rural Development, Fisheries and Food (SAGARPA), is undertaking the analysis of typical production units TPU in the agricultural and livestock sectors, by means of adapting simulation models originally developed for the United States of America. TPU are defined by means of panels in which producers provide technical and economic data (cost of production, profit, etc.) in order to carry out a micro-economic analysis of a base year and its 10-year projection, making assumptions on the development of prices derived from macro-economic analysis. This methodology has not been applied for the case of fisheries up to now, so the project has begun by considering small scale fisheries (for abalone and lobster at the west coast of the Baja California peninsula) and industrial fisheries (the sardine fishery in the Gulf of California). In this study we present the ongoing results on the definition of TPU. For the first one, classification criteria include geographical location, as well as their organization, production and social impact levels; three TPU were defined. For the second, the kind of fishing vessels and the degree to which the freezing, canning and reduction processes are integrated; however, we ended up considering exclusively the type of fishing boats to define two TPU. Each TPU is hereby described and discussed within the framework of each fishery and their historical development.Keywords: Fisheries Economics, Markets and Trad

Is the Weight of the Newborn Puppy Related to Its Thermal Balance?

Newborns experience a significant thermal change at birth, leading their bodies to adjust and reduce their metabolism to survive. In this study, newborn puppies’ weights and their temperatures in different body areas and at different measure times were evaluated to determine if there is a relationship between weight and their ability to reach thermostability. It was observed that there is a positive relationship between the weight of the puppies and their thermoregulatory capacity

The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes

Background &amp; Aims: We examined the impact of a co-diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2D) on patient outcomes.Methods: Using TriNetX, a global federated research network (n=114 million), we undertook two retrospective cohort studies, using time-to-event analysis. Analysis 1 compared MASLD with T2D to MASLD alone; analysis 2 compared T2D with MASLD to T2D alone. Propensity score matching using greedy nearest neighbour (calliper 0.1) balanced the cohorts (1:1) for significant covariates. Primary outcomes were cardiovascular, liver, diabetes-related, and cancer events over five years. Results: Analysis 1 (n=95,275): a co-diagnosis of T2D significantly increased the risk of ischaemic heart disease (IHD) (HR 1.39; CI: 1.34, 1.44), ischaemic stroke (HR 1.45; CI: 1.35, 1.56), heart failure (HR 1.42; CI: 1.36, 1.49), atrial fibrillation (HR 1.09; CI: 1.03, 1.16), hepatocellular carcinoma (HR 1.96; CI: 1.69, 2.27), pancreatic cancer (HR 1.25; CI: 1.06, 1.48) and liver-related complications over five years from MASLD diagnosis. Analysis 2 (n=15,208): a co-diagnosis of MASLD significantly increased risk of all-cause mortality (HR 1.11; CI: 1.02, 1.22), IHD (HR 1.181; CI: 1.08, 1.29), hepatocellular (HR 50.31; CI: 6.94, 364.72), pancreatic (HR 1.78; CI: 1.12, 2.84), breast (HR 1.43; CI: 1.09, 1.88) and renal cancer (HR 2.01; CI: 1.24, 3.26), and diabetic neuropathy (HR 1.17; CI: 1.09, 1.27) over five years from metformin initiation. Conclusions: T2D significantly potentiates risk of cardiovascular, malignancy, and liver-related outcomes in people with MASLD. The effect of MASLD on people with T2D, although less dramatic, still potentiated risk of death, IHD, malignancy, and peripheral neuropathy. Abstract word count: 256<br/

Cardiovascular Outcomes with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Diabetes: A Real-World Data Analysis.

BackgroundAnti-vascular endothelial growth factor (anti-VEGF) therapy is commonly used intravitreally for diabetic proliferative retinopathy, but when used systemically for treating cancers, an excess of cardiovascular disease (CVD) events has been noted. The latter is of concern for people with diabetes, who are at higher risk of CVD. This study aims to explore the relationship between incident CVD and intravitreal anti-VEGF therapy in patients with diabetes, compared to other therapies, using a large real-world global federated dataset.MethodsData were analysed using TriNetX, a global electronic medical real-world ecosystem. The study included adults with diabetes and excluded those with a history of CVD prior to the time window of data extraction. Patients were categorised into two cohorts: anti-VEGF therapy or control cohort (laser or steroid therapies). The cohorts were 1:1 propensity score-matched for age, sex, ethnicity, body mass index, systolic blood pressure, HbA1c, and cardiovascular medications. Outcomes analysed at 1, 6 and 12 months were: (1) mortality; (2) acute myocardial infarction (MI); (3) cerebral infarction; and (4) heart failure. Relative risk analyses were performed using the built-in R statistical computing platform on TriNetX.ResultsIn patients with diabetes (n = 2205; mean age 58.8 ± 15.8, Std diff 0.05; 56% male), anti-VEGF therapy was associated with a numerical but non-statistically significant increased CVD risk over 1, 6, and 12 months: Mortality over 1 month (RR 1; 95% CI 0.42, 2.40), 6 months (RR 1.46; 95% CI 0.72, 2.95) and 12 months (RR 1.41; 95% CI 0.88, 2.27). There was no excess of acute MI over 1 (RR n/a: not applicable; 0/0: 0 events in the anti-VEGF group/0 events in the control group), 6 and 12 months (RR n/a; 0/10 events); cerebral infarction over 1, 6 months (RR n/a; 0/0 events), and 12 months (RR n/a; 0/10); and heart failure over 1 month (RR n/a; 0/0 events), 6 months (RR 1; 95% CI 0.42, 2.40) and 12 months (RR 1; 95% CI 0.42, 2.34).ConclusionsThere was no statistically significant risk of cardiovascular-related events in the short or medium term in patients with diabetes who received intravitreal anti-VEGF therapy, despite a small increase in the number of CVD events. Our study supports the real-world safety of intravitreal anti-VEGF therapy in patients with diabetes free of baseline CVD

Cardiovascular outcomes with intravitreal anti-vascular endothelial growth factor therapy in patients with diabetes: a real-world data analysis

Background: Anti-vascular endothelial growth factor (anti-VEGF) therapy is commonly used intravitreally for diabetic proliferative retinopathy, but when used systemically for treating cancers, an excess of cardiovascular disease (CVD) events has been noted. The latter is of concern for people with diabetes, who are at higher risk of CVD. This study aims to explore the relationship between incident CVD and intravitreal anti-VEGF therapy in patients with diabetes, compared to other therapies, using a large real-world global federated dataset. Methods: Data were analysed using TriNetX, a global electronic medical real-world ecosystem. The study included adults with diabetes and excluded those with a history of CVD prior to the time window of data extraction. Patients were categorised into two cohorts: anti-VEGF therapy or control cohort (laser or steroid therapies). The cohorts were 1:1 propensity score-matched for age, sex, ethnicity, body mass index, systolic blood pressure, HbA1c, and cardiovascular medications (n=1822). Outcomes analysed at 1, 6 and 12 months were: 1) mortality; 2) acute myocardial infarction (MI); 3) cerebral infarction; and 4) heart failure. Relative risk analyses were performed using the built-in R statistical computing platform on TriNetX. Results: In patients with diabetes (n=2205; mean age 58.8±15.8, SD 0.05; 56% male), anti-VEGF therapy was associated with a numerical but non-statistically significant increased CVD risk over 1, 6, and 12 months: Mortality over 1 month (RR 1; 95% CI 0.42,2.40), 6 months (RR 1.46; 95%CI 0.72,2.95) and 12 months (RR 1.41; 95%CI 0.88,2.27). There was no excess of acute MI over 1 (RR n/a: not applicable; 0/0: 0 events in the anti-VEGF group/0 events in the control group), 6 and 12 months (RR n/a; 0/10 events); cerebral infarction over 1, 6 months (RR n/a; 0/0 events), and 12 months (RR n/a; 0/10); and heart failure over 1 month (RR n/a; 0/0 events), 6 months (RR 1; 95%CI 0.42,2.40) and 12 months (RR 1; 95%CI 0.42,2.34). Conclusion: There was no statistically significant risk of cardiovascular-related events in the short or medium term in patients with diabetes who received intravitreal anti-VEGF therapy, despite a small increase in the number of CVD events. Our study supports the real-world safety of intravitreal anti-VEGF therapy in patients with diabetes free of baseline CVD.  <br/